Literature DB >> 25935702

Precision and predictive medicine in urothelial cancer: are we making progress?

Joaquim Bellmunt1, Anna Orsola2, Guru Sonpavde3.   

Abstract

Therapy for urothelial carcinoma appears poised for a breakthrough on the basis of information regarding molecular subtypes and promising activity of PD-1/PD-L1 inhibitors. Precision medicine may be possible using rational marker-driven trial designs with enriched information from tumor genotyping and extreme responders.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25935702     DOI： 10.1016/j.eururo.2015.04.025

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  4 in total

1.  Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.

Authors:  Darshan S Chandrashekar; Balabhadrapatruni V S K Chakravarthi; Alyncia D Robinson; Joshua C Anderson; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Marie-Lisa Eich; Akhilesh Kumar Bajpai; Sravanthi Davuluri; Maya S Guru; Arjun S Guru; Gurudatta Naik; Deborah L Della Manna; Kshitish K Acharya; Shannon Carskadon; Upender Manne; David K Crossman; James E Ferguson; William E Grizzle; Nallasivam Palanisamy; Christopher D Willey; Michael R Crowley; George J Netto; Eddy S Yang; Sooryanarayana Varambally; Guru Sonpavde
Journal:  Oncogene       Date:  2020-03-30       Impact factor: 9.867

Review 2.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

3.  Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.

Authors:  Nakho Chang; Hye Won Lee; Joung Eun Lim; Da Eun Jeong; Hye Jin Song; Sudong Kim; Do-Hyun Nam; Hyun Hwan Sung; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han-Yong Choi; Hwang Gyun Jeon
Journal:  Oncotarget       Date:  2016-08-09

4.  PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.

Authors:  Takashi Kawahara; Yukari Ishiguro; Shinji Ohtake; Ikuma Kato; Yusuke Ito; Hiroki Ito; Kazuhide Makiyama; Keiichi Kondo; Yasuhide Miyoshi; Yasushi Yumura; Narihiko Hayashi; Hisashi Hasumi; Kimito Osaka; Kentaro Muraoka; Koji Izumi; Jun-Ichi Teranishi; Hiroji Uemura; Masahiro Yao; Noboru Nakaigawa
Journal:  BMC Urol       Date:  2018-11-06       Impact factor: 2.264
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.